Antibody–drug conjugates (ADCs) represent an emerging new paradigm in cancer therapy.
The approval of two ADCs has spurred considerable interest in this area of research, and …

Antibody–drug conjugates (ADCs) have become a major class of oncology
biopharmaceuticals. Traditional ADCs have a stochastic distribution of cytotoxic drugs …

ABSTRACT Introduction: Antibody-Drug Conjugates (ADCs) are becoming increasingly
important weapons in the fight against cancer, as evidenced by the growing number of …

This work examines the effect of three anions from the Hofmeister series (sulfate, chloride,
and thiocyanate) on the conformational stability and aggregation rate of an IgG1 monoclonal …

Antibody–drug conjugates (ADCs) are emerging therapeutic agents in the treatment of
cancer, and various conjugation strategies and chemical linkers have been developed to …

Non-cleavable linkers are used in a number of different modalities for various reasons, such
as linking an active drug moiety to half-life extending molecules, to groups that enable a …

Changes in non-native aggregation mechanisms of an anti-streptavidin (anti-SA) IgG1
antibody were determined over a wide range of pH and [NaCl] under accelerated (high …

Systemic chemotherapy, the current standard of care for the treatment of cancer, is rarely
curative and is often accompanied by debilitating side effects. Targeted drug delivery stands …

This study introduces a novel analytical approach for studying aggregation and phase
separation of monoclonal antibodies (mAbs). The approach is based on using analytical …

Antibody drug conjugates (ADCs) are synthesized by conjugating a cytotoxic drug or
“payload” to a monoclonal antibody. The payloads are conjugated using amino or sulfhydryl …